2021
Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma.
Patel KK, Giri S, Parker TL, Bar N, Neparidze N, Huntington SF. Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma. Journal Of Clinical Oncology 2021, 39: 1119-1128. PMID: 33411586, DOI: 10.1200/jco.20.01849.Peer-Reviewed Original ResearchConceptsTransplant-ineligible patientsIncremental cost-effectiveness ratioFirst-line settingHealthcare costsClinical outcomesMultiple myelomaProgression-free survivalOverall survival dataUS payer perspectiveDirect healthcare costsCost-effectiveness ratioRandomized trialsDisease progressionTreatment strategiesParametric survival modelingPayer perspectiveSubsequent linesLater linesPatientsCostly treatmentIncremental costQALYSurvival dataLenalidomideMyeloma
2019
Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment.
Huntington SF. Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment. Hematology 2019, 2019: 252-259. PMID: 31808838, PMCID: PMC6913455, DOI: 10.1182/hematology.2019000030.Peer-Reviewed Original ResearchConceptsFirst-line treatmentClassic Hodgkin lymphomaBrentuximab vedotinNovel therapiesLarge-scale clinical trialsLarge randomized trialsHodgkin lymphoma treatmentRisk of progressionStandard cytotoxic therapiesChemotherapy cyclesDurable remissionsMultiagent chemotherapyMost patientsClinical outcomesRandomized trialsMedical oncologyCytotoxic therapyHodgkin's lymphomaLymphoma treatmentClinical trialsSelect populationIncomplete responseAlkylator chemotherapyChemotherapyAdvanced stage
2016
Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes
Zeidan AM, Davidoff AJ, Long JB, Hu X, Wang R, Ma X, Gross CP, Abel GA, Huntington SF, Podoltsev NA, Hajime U, Prebet T, Gore SD. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. British Journal Of Haematology 2016, 175: 829-840. PMID: 27650975, DOI: 10.1111/bjh.14305.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeRAEB patientsMedian survivalClinical trialsMultivariate Cox proportional hazards modelCox proportional hazards modelKaplan-Meier methodPopulation-based survivalSignificant survival differenceComparative clinical effectivenessProportional hazards modelAgent azacitidineHMA initiationExcess blastsOlder patientsRandomized trialsHistological subtypesRefractory anemiaClinical effectivenessSurvival differencesSubset analysisSurvival advantageHazards modelPatientsDecitabine